The manufacturer of Protonix, Wyeth Pharmaceuticals, in their package insert for the drug is available online and states the following:. An alternative confirmatory method should be considered to verify positive results. Quest Diagnostics is not aware of any reports of false positive screens for marijuana with the technology utilized in our screening tests for cannabinoids.
Consequently, the use of Protonix should not result in a confirmed positive drug test for marijuana or its metabolite. For more information about drug testing, visit our website or contact us online.
Urine testing in the detection of drugs of abuse. Arch Intern Med ; : — Brunk SD. J Anal Toxicol ; 12 5 : — 1. A maximum common substructure-based algorithm for searching and predicting drug-like compounds.
Bioinformatics ; 24 13 : i — ChemMine tools: An online service for analyzing and clustering small molecules. Nucleic Acids Res ; 39 : W — Oxford University Press is a department of the University of Oxford.
It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Sign In or Create an Account. Sign In. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents Abstract. Results and Discussion. Correspondence to: Jennifer L. Tel: ; Fax: ; E-mail: powers. Oxford Academic.
Natalie N Rasmussen, BS. Dow Hurst, BS. Frederick G Strathmann, PhD. PDF Views. Select Format Select format. Permissions Icon Permissions. Abstract Objective. Figure 1. Open in new tab Download slide. Number of Samples.
Open in new tab. Figure 2. Google Scholar PubMed. Google Scholar Crossref. Search ADS. All rights reserved. For permissions, please e-mail: journals. Issue Section:. Download all slides. View Metrics. Email alerts Article activity alert. Advance article alerts. New issue alert. Receive exclusive offers and updates from Oxford Academic. Patients with concomitant medication known to cause cross-reactivity in THC immunoassays evaluated were excluded.
Demographic and clinic characteristics of these patients are shown in Table I. Parents of all participants signed an informed consent form. Ethical approval for the study was obtained from the institutional Research Ethics Committee. Three urine samples were collected from each patient, one before treatment and two in different phases of their treatment with pantoprazole.
The samples were kept frozen until analysis. Table I. Summary of patient characteristics. Results of the in vitro cross-reactivity study are shown in Table II. Table II. Cannabinoid immunoassay response and confirmation results for samples fortified with pantoprazole.
In the in vivo study with pediatric patients, baseline urine specimens were available for all participants. These specimens were screened for cannabinoids in the three immunoassays, and results were negative. Table III presents data for the responses of immunoassays to urine samples from patients undergoing pantoprazole therapy. Table III.
Cannabinoid immunoassay response and confirmation results for screened patient samples. These results showed that this immunoassay was subject to attributable interference to pantoprazole. THC metabolite concentrations by GC—MS were undetectable in all samples, confirming false-positive results for immunoassays.
The pharmacokinetics of pantoprazole in man has been extensively studied 8 , 9 , Pantoprazole is rapidly absorbed after oral administration, with peak plasma at 2. Metabolism of pantoprazole is independent of the route of administration and occurs in the liver through the cytochrome P system. The hydroxylated metabolites then undergo phase II metabolism, i. There was no unchanged pantoprazole found in urine or in faeces.
Concretely, in the US Emergency Departments, pantoprazole was the agent with the largest increase in use In these patients, it is important to be aware of the potential for a PPI to cause a false-positive urine cannabinoid screening and confirm all presumptive positive results. The main metabolites of the pantoprazole were not included in any of the studies performed because their analytical standards could not be purchased. It is important to recognize that drug metabolites, and not the parent drug, can probably cause false-positive results in patient samples too.
Saitman , A. Journal of Analytical Toxicology , 38 , — Google Scholar. Bosy , T. Journal of Analytical Toxicology , 24 , — Rollins , D. Clinical Chemistry , 36 , — Kovatsi , L. Journal of Analytical Toxicology , 34 , — Rossi , S.
Clinical Chemistry , 52 , — Cotton , S. Clinical Biochemistry , 45 , — Protonix, delayed release package insert. Last revised Oct. Ward , R. Paediatric Drugs , 15 , — Litalien , C.
Clinical Pharmacokinetics , 44 , —
0コメント